# Karuna Therapeutics, Inc. – Consensus ‘buy’ rating and 22.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.consensus-buy-rating-and-22.3-upside-potential/4121136115
- Published: 2023-12-15T13:19:49+00:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** with ticker code (KRTX) now have 20 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between $320.00 and $197.00 with the average target price sitting
at $266.55. Given that the stocks previous close was at $217.86 and the analysts
are correct then there would likely be a percentage uptick in value of 22.3%. It’s
also worth noting that there is a 50 day moving average of $180.74 and the 200 moving
average now moves to $193.74. The company has a market capitalization of 8.27B. 
The stock price for the company is currently $219.12 USD

 The potential market cap would be $10,114,318,088 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of $0.16 and a -21.51% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on:
